Real-World Data on Inotuzumab Ozogamicin for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A...

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Inotuzumab Ozogamicin (InO) efficacy is established in relapsed/refractory acute lymphoblastic leukemia (R/R ALL).
• Limited data exists on InO outcomes in Latin America.
• This study evaluates InO treatment in Chilean patients with R/R ALL.

Purpose of the Study:

• To assess the efficacy and safety of Inotuzumab Ozogamicin in Chilean patients with R/R ALL.
• To identify prognostic factors influencing treatment outcomes.
• To compare outcomes with existing international research.

Main Methods:

• Retrospective analysis of 35 R/R ALL patients treated with InO.
• Assessment of response rates, measurable residual disease (MRD), survival, and toxicities.
• Multivariate analyses to explore prognostic factors.

Main Results:

• 74% of patients achieved complete remission or remission with incomplete recovery (CR/CRi).
• 82% achieved MRD negativity (<0.01%).
• Allogeneic stem cell transplant (Allo-HSCT) post-InO significantly improved overall survival (24.2 vs. 5.2 months).
• Median PFS was 6.9 months and median OS was 8.8 months.
• Sinusoidal obstruction syndrome (SOS) occurred in 14% but was generally mild.
• Comorbidities and high blast counts were adverse prognostic factors.
• MRD negativity and subsequent Allo-HSCT were associated with improved outcomes.

Conclusions:

• InO demonstrates high remission and MRD negativity rates in Chilean R/R ALL patients.
• Outcomes are comparable to existing research, with generally mild SOS.
• Achieving MRD negativity and undergoing Allo-HSCT are key for improved survival.
• Further research with longer follow-up is warranted.